Abstract
The widespread introduction of penicillin in the 1940s resulted in a substantial reduction in mortality from community-acquired pneumonia (CAP). However, despite significant advances in medical science, only a small improvement has occurred since, particularly in patients with bacteremic pneumococcal pneumonia [1, 2]. Even modern intensive care has only made a small difference to the mortality in patients with severe pneumonia [3, 4]. While the aging population, increased number of patients with severe co-morbid illnesses, and the human immunodeficiency virus (HIV) epidemic have certainly contributed to the persistently high mortality rate [2, 5, 6], apparently healthy, immunocompetent patients continue to die from CAP. Disturbingly, a recent British Thoracic Society study concluded that no available therapy could substantially reduce the mortality rate from severe CAP in young adults [7].
Chapter PDF
Similar content being viewed by others
Keywords
- Acute Respiratory Failure
- Noninvasive Ventilation
- Extracorporeal Life Support
- Miliary Tuberculosis
- Partial Liquid Ventilation
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Burman LA, Norrby R, Trollfors B (1985) Invasive pneumococcal infections: incidence, predisposing factors and prognosis. Rev Infect Dis 7:133–142
Watankunakorn C, Bailey TA (1997) Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992–1996. Arch Intern Med 157:1965–1971
Hook EW, Horton CA, Schaberg DR (1983) Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 249:1055–1057
Franklin C, Henrickson K, Weil MH (1991) Reduced mortality of pneumococcal bacteremia after early intensive care. J Intensive Care Med 6:302–307
Torres JM, Cardenas O, Vasquez A, Schlossberg D (1998) Streptococcus pneumoniae bacteremia in a community hospital. Chest 113:387–390
Plouffe JF, Breiman RF, Facklam RR, Franklin County Pneumonia Study Group (1996) Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. JAMA 275:194–198
Simpson JC, Macfarlane JT, Watson J, Woodhead MA (2000) A national confidential enquiry into community acquired pneumonia deaths in young adults in England and Wales. British Thoracic Society Research Committee and Public Health Laboratory Service. Thorax 55(12):1040–5
Gagnon S, Ahmad M, Boota ND, et al. (1990) Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 323:1444–1450
Bozette SA, Sattler FR, Chiu J, et al. (1990) A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 323:1451–1457
Mer M, Richards GA (1998) Corticosteroids in life-threatening varicella pneumonia. Chest 114:426–431
Goldman M, Johnson PC, Sarosi GA (1999) Fungal pneumonias. The endemic mycoses. Clin Chest Med 20:507–519
Bradsher RW (1996) Histoplasmosis and blastomycosis. Clin Infect Dis 22:S102–S111
Tognian S, Jiayu Y, Liye Z, Weiwu D, Zhaoying S (1981) Chemotherapy and its combination with corticosteroids in acute miliary tuberculosis in adolescents and adults: analysis of 55 cases. Chin Med J 94:309–314
Lebel MH, Freij BJ (1988) Dexamethasone therapy for bacterial meningitis: results of two double-blind, placebo controlled trials. N Engl J Med 319:964–971
Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW (1993) Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. Chest 104:389–392
Klugman K (1990) Pneumococcal resistance to antibiotics. Clin Microbiol Rev 3:171–196
Monton C, Ewig S, Torres A, et al. (1999) Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J 14(1):218–20
Confalonieri M, Urbino R, Potena A, et al. (2005) Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 171(3):242–8
Confalonieri M, Potena A, Carbone G, Porta RD, Tolley EA, Umberto Meduri G (1999) Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 160(5):1585–91
Light RB (1986) Indomethacin and acetylsalicylic acid reduce intrapulmonary shunt in experimental pneumococcal pneumonia. Am Rev Respir Dis 134:520–525
Hanley PJ, Roberts D, Dobson K, et al. (1987) Effect of indomethacin on arterial oxygenation in critically ill patients with severe pneumonia. Lancet 1:351–354
Bernard GR, Reines HD, Halushka RV, Higgins SB, Metz CA, Swindell BB, et al. (1991) Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Am Rev Respir Dis 144:1095–1101
Ferrer M, Torres A, Baer R, Hernández C, Roca J, Rodriguez-Roisin R (1997) Effect of acetylsalicylic acid on pulmonary gas exchange in patients with severe pneumonia: a pilot study. Chest 111:1094–1100
Dowling HF, Lepper MH (1951) The effect of antibiotics (penicillin, aureomycin, and terramycin) on the fatality rate and incidence of complications in pneumococcic pneumonia. A comparison with other methods of therapy. Am J Med Sci 222:396–403
Kohzuki T, Eguchi Y, Kato M, Irie K, Ohtsuka H, Higuchi A, et al. (1993) Protective activity of anti-exotoxin A monoclonal antibody against mice infected with toxin-producing Pseudomonas aeruginosa. J Infect Dis 167:119–125
Hector RF, Collins MS, Pennington JE (1989) Treatment of experimental Pseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody. J Infect Dis 160:483–489
Pennington JE, Hickey WF, Blackwood LL, et al. (1981) Active immunization with lipopolysaccharide Pseudomonas antigen for chronic Pseudomonas bronchopneumonia in guinea pigs. J Clin Invest 68:1140–1148
Saravolatz LD, Markowitz N, Collins MS, Bogdanoff D, Pennington JE (1991) Safety, pharmokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients. J Infect Dis 167:784–785
Greenman RL, Schein RMH, Martin MA, et al. (1991) A controlled trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097–1102
Ziegler EJ, Fisher CJ, Sprung CL, et al. (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double blind, placebo-controlled trial. N Engl J Med 324:429–436
Klimek JJ, Ajemian E, Tontecchio S, Gracewski J, Klemas B, Jiminez L (1983) Community-acquired bacterial pneumonia requiring admission to hospital. Am J Infect Control 11:79–82
Aubertin J, Dabis F, Fleurett J, Bornstein N, Salamon R, Brottier E, et al. (1987) Prevalence of legionellosis among adults: a study of community-acquired pneumonia in France. Infection 15:328–331
Fang GD, Fine MJ, Orloff J, Arisumi D, Yu VL, Kapoor W, et al. (1990) New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine 69:307–316
Lieberman D, Schlaeffer F, Boldur I, Horowitz S, Friedman MG, Leiononen M, et al. (1996) Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 51:179–184
Tateda K, Matsumoto T, Ishii Y, Furuya N, Ohno A, Miyazaki S, et al. (1998) Serum cytokines in patients with Legionella pneumonia: relative predominance of Th1-type cytokines. Clin Diag Lab Immunol 5:401–403
Friedman H, Yamamoto Y, Newton C, Klein T (1998) Immunologic response and pathophysiology to Legionella infection. Semin Resp Infect 13:100–108
Murray HW(1989) Interferon-gamma, the activated macrophage, and host defense against microbial challenge. Ann Intern Med 108:608
Nathan CF, Prendergast TJ, Wiebe ME, Stanley ER, Platzer E, Remold HG, et al. (1984) In vivo and in vitro activation of alveolar macrophages by recombinant interferon-γ. J Exp Med 160:600–605
Skerrett SJ, Martin TR (1994) Intratracheal interferon-γ augments pulmonary defenses in experimental legionellosis. Crit Care Med 149:50–58
Jaffe R, Buhl R, Mastrangeli A, Holroyd KJ, Saltini C, Czerski D, et al. (1991) Organ specific cytokine therapy. J Clin Invest 88:297–302
Condos R, Rom WN, Schluger NW (1997) Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 349:1513–1515
Bernard GR, Vincent JL, Laterre PF, et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10):699–709
Laterre PF, Garber G, Levy H, et al. (2005) Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 33(5):952–61
Ely EW, Laterre PF, Angus DC, et al. (2003) Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 31(1):12–9
Remolina C, Khan AU, Santiago TV, et al. (1981) Positional hypoxemia in unilateral lung disease. N Engl J Med 304:523
Carlon GC, Ray CR, Klein R, et al. (1978) Criteria for selective positive end-expiratory pressure and independent synchronized ventilation of each lung. Chest 74:501–507
Hillman KM, Barber JD (1980) Asynchronous independent lung ventilation (AILV). Crit Care Med 8:390–395
Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, Brienza A, et al. (1999) Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 282:77–78
Zapol WM, Snider MT, Hill JD (1979) Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study. JAMA 242:2193
ECMO Registry of the Extracorporeal Life Support Organization (ELSO) (1997) ECMO Quarterly Report January 1997
Green TP, Timmons OD, Fackler JC, Moler FW, Thompson AE, Sweeney MF, et al. (1996) The impact of extracorporeal membrane oxygenation on survival in pediatric patients with acute respiratory failure. Crit Care Med 24:323–329
Masiakos PT, Islam S, Doody DP, Schnitzer JJ, Ryan DP (1999) Extracorporeal membrane oxygenation for nonneonatal acute respiratory failure. Arch Surg 134:375–379
Meyer TA, Warner BW (1997) Extracorporeal life support for the treatment of viral pneumonia: collective experience from the ELSO registry. J Pediatr Surg 32:232–236
Kolla S, Awad SS, Rich PB, Schreiner RJ, Hirschl RB, Bartlett RH (1997) Extracorporeal life support for 100 adult patients with severe respiratory failure. Ann Surg 226:544–564
Ichiba S, Jenkins DR, Peek GJ, Brennan KJ, Killer HM, Sosnowski A, et al. (1999) Severe acute respiratory failure due to legionella pneumonia treated with extracorporeal membrane oxygenation. Clin Infect Dis 28:686–687
Nakajima H, Kutsuwada T, Ohdaira T, Saito A, Satoh K, Igarashi K, et al. (1997) Extracorporeal membrane oxygenation for acute respiratory failure induced by Legionella pneumoniae. Nihon Kyobu Shikkan Gakkai Zasshi 35:1363–1367
Codispoti M, Sanger K, Mankad PS (1995) Successful extracorporeal membrane oxygenation (ECMO) support for fulminant community-acquired pneumococcal pneumonia. Thorax 50:1317–1319
Lee WA, Kolla S, Schreiner RJ, Hirschl RB, Bartlett RH (1997) Prolonged extracorporeal life support for varicella pneumonia. Crit Care Med 25:997–982
Crowley MR, Katz RW, Kessler R, Simpson SQ, Levy H, Hallin GW, et al. (1998) Successful treatment of adults with severe Hantavirus pulmonary syndrome with extracorporeal membrane oxygenation. Crit Care Med 26:409–414
Dickson EW, Heard SO, Chu B, Fraire A, Brueggemann AB, Doern GV (1998) Partial liquid ventilation with perfluorocarbon in the treatment of rats with lethal pneumococcal pneumonia. Anesthesiology 88:218–223
Quezado ZM, Natanson C, Karzai W, Danner RL, Koev CA, Fitz Y, et al. (1998) Cardiopulmonary effects of inhaled nitric oxide in normal dogs and during E. coli pneumonia and sepsis. J Appl Physiol 84:107–115
Anggard E (1994) Nitric oxide: mediator, murderer, and medicine. Lancet 343:1199–1206
Hoehn T, Huebner J, Paboura E, Krause M, Leititis JU (1998) Effect of therapeutic concentrations of nitric oxide on bacterial growth in vitro. Crit Care Med 26:1857–1862
Chollet-Martin S, Gatecel C, Kermarrec N, Gougerot-Pocidalo M, Payen DM (1996) Alveolar neutrophil functions and cytokine levels in patients with the adult respiratory distress syndrome during nitric oxide inhalation. Am J Respir Crit Care Med 153:985–990
Walmrath D, Schneider T, Pilch J, Schermuly R, Grimminger F, Seeger W (1995) Effects of aerosolized prostacyclin in severe pneumonia. Am J Respir Crit Care Med 151:724–730
Confalonieri M, Potena A, Carbone G, Della Porta R, Tolley EA, Meduri GU (1999) Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 160:1585–1591
Joshi N, Localio AR, Hamory BH (1992) A predictive risk index for nosocomial pneumonia in the intensive care unit. Am J Med 93:135–142
Olivier KN, Bennett WD, Hohneker KW, Zeman KL, Edwards LJ, Boucher RC, et al. (1996) Acute safety and effects on mucociliary clearance of aerosolized uridine 5′-triphospate ±amiloride in normal human adults. Am J Respir Crit Care Med 154:217–223
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Waterer, G.W., Wunderink, R.G. (2007). Adjunctive and Supportive Measures for Community-Acquired Pneumonia. In: Rello, J., Kollef, M., DÃaz, E., RodrÃguez, A. (eds) Infectious Diseases in Critical Care. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34406-3_38
Download citation
DOI: https://doi.org/10.1007/978-3-540-34406-3_38
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-34405-6
Online ISBN: 978-3-540-34406-3
eBook Packages: MedicineMedicine (R0)